SHAMAN TO TEST HERPES DRUGShaman Pharmaceuticals Inc. announced Tuesday at the Alex.Brown & Sons 18th Annual Health Care Seminar in Baltimorethat it intends to initiate clinical studies of its topical anti-viralproduct, Virend, in AIDS patients with secondary herpesinfection.
Shaman (NASDAQ:SHMN) of South San Francisco, Calif., isalready conducting Phase I trials on Virend in acyclovir-resistant AIDS patients. Patient enrollment for that trial, whichbegan in January, is "proceeding on schedule," according to LisaConte, president and chief executive officer. Before it canexpand the patient population, Shaman still needs to completepreclinical tests, build product inventory, and submit anamendment to its investigational new drug (IND) applicationfor Virend, said Rozanne Rapozo, company vice president.
(c) 1997 American Health Consultants. All rights reserved.